Caribou Biosciences (CRBU) Accumulated Expenses (2020 - 2026)

Caribou Biosciences (CRBU) has reported Accumulated Expenses for 7 consecutive years, with $13.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses fell 30.16% year-over-year to $13.9 million; the TTM figure through Mar 2026 stood at $13.9 million (down 30.16% YoY), while the FY2025 annual figure was $16.5 million, down 30.0% from the prior year.
• Accumulated Expenses fell to $13.9 million in Q1 2026 per CRBU's latest filing, from $16.5 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $25.4 million in Q3 2024 and bottomed at $100000.0 in Q1 2022.
• Historically, Accumulated Expenses has averaged $16.5 million across 5 years, with a median of $18.2 million in 2023.
• On a YoY basis, Accumulated Expenses climbed as much as 14637900.0% in 2022 and fell as far as 98.5% in 2022.
• Caribou Biosciences' Accumulated Expenses stood at $16.1 million in 2022, then surged by 31.44% to $21.1 million in 2023, then rose by 11.76% to $23.6 million in 2024, then dropped by 30.0% to $16.5 million in 2025, then fell by 16.0% to $13.9 million in 2026.
• Business Quant data shows CRBU's Accumulated Expenses at $13.9 million in Q1 2026, $16.5 million in Q4 2025, and $19.3 million in Q3 2025.